Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;20(12):1288-1298.
doi: 10.6004/jnccn.2022.0063.

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023

Edward M Schaeffer  1 , Sandy Srinivas  2 , Nabil Adra  3 , Yi An  4 , Daniel Barocas  5 , Rhonda Bitting  6 , Alan Bryce  7 , Brian Chapin  8 , Heather H Cheng  9 , Anthony Victor D'Amico  10 , Neil Desai  11 , Tanya Dorff  12 , James A Eastham  13 , Thomas A Farrington  14 , Xin Gao  15 , Shilpa Gupta  16 , Thomas Guzzo  17 , Joseph E Ippolito  18 , Michael R Kuettel  19 , Joshua M Lang  20 , Tamara Lotan  21 , Rana R McKay  22 , Todd Morgan  23 , George Netto  24 , Julio M Pow-Sang  25 , Robert Reiter  26 , Mack Roach  27 , Tyler Robin  28 , Stan Rosenfeld  29 , Ahmad Shabsigh  30 , Daniel Spratt  16 , Benjamin A Teply  31 , Jonathan Tward  32 , Richard Valicenti  33 , Jessica Karen Wong  34 , Ryan A Berardi  35 , Dorothy A Shead  35 , Deborah A Freedman-Cass  35
Affiliations

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023

Edward M Schaeffer et al. J Natl Compr Canc Netw. 2022 Dec.

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

PubMed Disclaimer